Salvinorin A, a hallucinogenic compound from the plant Salvia divinorum, is a potent and selective activator of the kappa-opioid receptor (KOR), a promising target for new painkillers. Unlike typical opioids, it lacks a basic nitrogen, enters the brain rapidly, and has a short duration of action. Since 2000, extensive medicinal chemistry using semi-synthesis from plant extracts has explored its properties. Total synthesis efforts have produced multiple routes to create salvinorin A and related analogs, aiming to improve its activity for various therapeutic effects. This review covers those total syntheses and identifies remaining challenges for future synthetic chemistry to address.
A new chemical synthesis method produces salvinorin analogs that are more potent, selective, stable, and functionally biased than the natural compound salvinorin A. These analogs target the kappa-opioid receptor and could serve as templates for next-generation pain relievers, anti-itch treatments, and dissociative hallucinogens. The synthesis uses a special organocatalyst and a cobalt-catalyzed cycloaddition to efficiently create a library of these complex molecules, overcoming previous difficulties in modifying their structure.